and get StockInvest.us Premium Subscription for FREE
Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
ACADIA Pharmaceuticals Inc. Stock Price (Quote) NASDAQ:ACAD
$15.27 ( 6.26% ) Tuesday, 5th Jul 2022
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $12.24 | $20.35 | Tuesday, 5th Jul 2022 ACAD stock ended at $15.27. This is 6.26% more than the trading day before Friday, 1st Jul 2022. During the day the stock fluctuated 7.99% from a day low at $14.15 to a day high of $15.28. |
| 90 days | $12.24 | $28.06 | |
| 52 weeks | $12.24 | $28.06 |
Historical ACADIA Pharmaceuticals Inc. prices
| Date | Open | High | Low | Close | Volume |
| 2022-07-05 | $14.29 | $15.28 | $14.15 | $15.27 | 2 207 547 |
| 2022-07-01 | $14.28 | $14.50 | $14.02 | $14.37 | 1 499 969 |
| 2022-06-30 | $14.03 | $14.31 | $13.93 | $14.09 | 1 592 267 |
| 2022-06-29 | $14.04 | $14.37 | $13.89 | $14.22 | 1 844 570 |
| 2022-06-28 | $14.62 | $14.72 | $13.87 | $14.00 | 2 721 404 |
| 2022-06-27 | $14.88 | $15.25 | $14.60 | $14.64 | 2 365 059 |
| 2022-06-24 | $14.84 | $15.48 | $14.35 | $14.98 | 3 829 524 |
| 2022-06-23 | $13.44 | $14.86 | $13.38 | $14.72 | 5 567 983 |
| 2022-06-22 | $12.75 | $13.61 | $12.68 | $13.43 | 5 887 902 |
| 2022-06-21 | $13.20 | $13.26 | $12.24 | $13.01 | 22 264 936 |
| 2022-06-17 | $19.51 | $19.51 | $19.51 | $19.51 | 0 |
| 2022-06-16 | $18.53 | $20.35 | $17.89 | $19.51 | 7 923 336 |
| 2022-06-15 | $17.39 | $19.58 | $17.14 | $18.77 | 20 608 443 |
| 2022-06-14 | $16.87 | $16.92 | $15.53 | $16.25 | 2 507 292 |
| 2022-06-13 | $16.55 | $16.80 | $15.89 | $16.77 | 2 795 721 |
| 2022-06-10 | $17.16 | $17.34 | $16.70 | $17.09 | 2 038 682 |
| 2022-06-09 | $17.91 | $18.08 | $17.36 | $17.43 | 1 277 022 |
| 2022-06-08 | $18.07 | $18.47 | $17.92 | $18.12 | 1 230 409 |
| 2022-06-07 | $16.78 | $18.36 | $16.78 | $18.27 | 1 888 501 |
| 2022-06-06 | $18.02 | $18.26 | $16.71 | $16.93 | 1 521 470 |
| 2022-06-03 | $16.16 | $17.94 | $16.11 | $17.90 | 2 531 055 |
| 2022-06-02 | $16.16 | $16.45 | $15.92 | $16.17 | 1 182 690 |
| 2022-06-01 | $16.24 | $16.86 | $15.86 | $16.37 | 1 454 345 |
| 2022-05-31 | $16.93 | $17.02 | $16.11 | $16.15 | 1 756 099 |
| 2022-05-27 | $16.23 | $17.11 | $15.92 | $17.08 | 1 329 896 |
| 2022-05-26 | $15.93 | $16.47 | $15.65 | $16.23 | 1 621 781 |
| 2022-05-25 | $16.02 | $16.29 | $15.45 | $15.96 | 991 791 |
| 2022-05-24 | $16.65 | $16.93 | $15.88 | $15.98 | 1 483 050 |
| 2022-05-23 | $17.33 | $17.43 | $16.48 | $16.79 | 1 171 330 |
| 2022-05-20 | $17.01 | $17.21 | $16.26 | $17.11 | 1 308 503 |
| 2022-05-19 | $16.07 | $17.12 | $16.07 | $16.83 | 1 627 795 |
| 2022-05-18 | $16.56 | $16.79 | $15.79 | $16.04 | 1 321 963 |
| 2022-05-17 | $17.03 | $17.23 | $16.61 | $17.05 | 1 407 957 |
| 2022-05-16 | $16.80 | $17.03 | $16.39 | $16.60 | 1 183 508 |
| 2022-05-13 | $16.36 | $16.93 | $16.18 | $16.85 | 2 642 224 |
| 2022-05-12 | $15.23 | $16.03 | $15.16 | $16.03 | 2 219 716 |
| 2022-05-11 | $16.64 | $16.87 | $15.16 | $15.29 | 2 041 231 |
| 2022-05-10 | $17.32 | $17.74 | $16.21 | $16.84 | 1 820 271 |
| 2022-05-09 | $17.45 | $17.76 | $16.31 | $16.38 | 2 577 406 |
| 2022-05-06 | $18.54 | $18.63 | $17.65 | $17.88 | 2 053 795 |
| 2022-05-05 | $19.51 | $19.88 | $18.71 | $18.83 | 1 643 207 |
| 2022-05-04 | $19.95 | $19.95 | $18.90 | $19.89 | 1 438 100 |
| 2022-05-03 | $19.57 | $20.50 | $19.45 | $19.81 | 1 752 683 |
| 2022-05-02 | $18.18 | $19.57 | $18.18 | $19.54 | 2 107 031 |
| 2022-04-29 | $18.88 | $19.23 | $18.40 | $18.44 | 1 460 686 |
| 2022-04-28 | $19.43 | $19.58 | $18.35 | $18.96 | 2 186 800 |
| 2022-04-27 | $19.00 | $19.57 | $18.70 | $18.99 | 1 849 089 |
| 2022-04-26 | $20.05 | $20.21 | $18.76 | $18.94 | 2 151 669 |
| 2022-04-25 | $20.13 | $20.47 | $19.73 | $20.26 | 1 453 400 |
| 2022-04-22 | $21.33 | $21.39 | $20.35 | $20.43 | 715 558 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzh... ![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
